InvestSMART

Nyrada Inc (ASX: NYR) - Announcements

- Current share price for NYR : $0.490

ASX company news and announcements for Nyrada Inc (NYR) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Nyrada Inc (NYR) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Nyrada Inc (NYR), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Nyrada Inc (NYR)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$127 NYR Appoints Consultant Cardiologist for Phase IIa Trial 13 Aug 2025 9:15AM $0.295 $0.490 risen by 66.10%
$127 Cleansing Statement 11 Aug 2025 9:53AM $0.300 $0.490 risen by 63.33%
$127 Application for quotation of securities - NYR 11 Aug 2025 9:52AM $0.300 $0.490 risen by 63.33%
$127 Positive Final Review of Nyrada Phase I Clinical Trial 6 Aug 2025 9:38AM $0.320 $0.490 risen by 53.13%
$127 BioShares Biotech Summit Presentation 6 Aug 2025 8:24AM $0.320 $0.490 risen by 53.13%
$127 Change in substantial holding - M Azzi 5 Aug 2025 10:25AM $0.330 $0.490 risen by 48.48%
$127 Cleansing Statement 4 Aug 2025 11:15AM $0.325 $0.490 risen by 50.77%
$127 Application for quotation of securities - NYR 4 Aug 2025 11:13AM $0.325 $0.490 risen by 50.77%
$127 Application for quotation of securities - NYR 4 Aug 2025 11:10AM $0.325 $0.490 risen by 50.77%
$127 Proposed issue of securities - NYR 4 Aug 2025 9:05AM $0.370 $0.490 risen by 32.43%
$127 Proposed issue of securities - NYR 4 Aug 2025 9:05AM $0.370 $0.490 risen by 32.43%
$127 Nyrada Successfully Raises $8.25 Million via Placement 4 Aug 2025 9:05AM $0.370 $0.490 risen by 32.43%
$127 Change in substantial holding - M Azzi 31 Jul 2025 12:44PM $0.370 $0.490 risen by 32.43%
$127 Trading Halt 31 Jul 2025 9:16AM $0.370 $0.490 risen by 32.43%
$127 Quarterly Activities Report and Appendix 4C 31 Jul 2025 8:40AM $0.370 $0.490 risen by 32.43%
$127 Top 20 CDI Holder List 31 Jul 2025 8:29AM $0.370 $0.490 risen by 32.43%
$127 NYR Advances Xolatryp Phase IIa Trial in Cardioprotection 23 Jul 2025 8:30AM $0.350 $0.490 risen by 40%
$127 Final Phase I Clinical Trial Patients Dosed and Discharged 21 Jul 2025 8:26AM $0.280 $0.490 risen by 75%
$127 Final Nyrada Phase I Clinical Trial Cohort to Commence 14 Jul 2025 9:14AM $0.270 $0.490 risen by 81.48%
$127 Notice of Change of Interests of Substantial Holder - M Azzi 4 Jul 2025 11:09AM $0.265 $0.490 risen by 84.91%
$127 Proposed issue of securities - NYR 30 Jun 2025 8:31AM $0.225 $0.490 risen by 117.78%
$127 Notice of Change of Interests of Substantial Holder - M Azzi 25 Jun 2025 12:15PM $0.225 $0.490 risen by 117.78%
$127 Phase I Clinical Trial Dosing Update No 4 16 Jun 2025 8:46AM $0.200 $0.490 risen by 145%
$127 Nyrada Investor Conference Call 16 Jun 2025 8:38AM $0.200 $0.490 risen by 145%
$127 Non-Deal Investor Presentation 16 Jun 2025 8:30AM $0.200 $0.490 risen by 145%

151 - 175 of 521 results

Page 7 of 21

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.